2024-518884-36-00招募中2 期
Antimalarial prophylactic efficacy of a weekly dose atovaquone-proguanil
Universitaetsklinikum Tuebingen AöR1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2024年11月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Efficacy endpoint Proportion of protected volunteers. Protection is defined as the absence of amplifying parasitaemia in the peripheral blood for +21 days following CHMI with PfSPZ Challenge (NF54) in volunteers receiving AP (250/100 mg) for chemoprophylaxis. Amplifying parasitaemia is defined as at least one qPCR result above 20 blood-stage parasites per ML followed by a second qPCR result with an at least 4-fold increased blood stage parasitaemia 24-48 hours apartPrimary safety endpoint Numbe
研究概览
简要总结
The overall primary objective is to evaluate the prophylactic efficacy of a weekly dose administration of oral AP 250/100 mg in non-immune healthy volunteers exposed to malaria by intravenous administration of heterologous PfSPZ Challenge (NF54).
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Healthy malaria-naive adults aged 18 to 40 years.
- •Willingness to take AP or placebo at the scheduled timepoint and a curative antimalarial regimen following CHMI and development of amplifying parasitaemia.
- •Answer all questions on the informed consent quiz correctly.
- •Able and willing (in the Investigator’s opinion) to comply with all study requirements
- •Willing to allow the investigators to discuss the volunteer’s medical history with their general practitioner if required.
- •Residence in or nearby Tübingen with a maximum travel time to our study centre of 1 hour for the study period
- •Women who agree to practice effective contraception for the duration of the study (a method which results in a low failure rate; i.e. less than 1% per year).
- •Weight over 40 kg and BMI ≥19 and ≤
- •Agreement to refrain from blood donation during the course of the study and after the end of their involvement in the study according to the local and national blood banking eligibility criteria
- •Provision of written informed consent to receive PfSPZ Challenge (NF54) for CHMI.
- •Reachable (24/7) by mobile phone during the CHMI period.
排除标准
- •History of malaria.
- •History of seizure (except uncomplicated febrile convulsion at childhood)
- •Pregnancy, lactation or intention to become pregnant during the study.
- •Diagnosis of any immune deficiency disorder, including human immunodeficiency virus (HIV) infection.
- •History of (functional) asplenia.
- •Use of chronic (more than 14 days) systemic immunosuppressive medication within the past 2 years (topical or inhaled immunosuppressive agents are allowed).
- •Any other confirmed or suspected immunosuppressive or immunodeficient state (e.g., repeated and/or unusual infection), including history of infection caused by opportunistic organisms, any infection or combination of infections that suggest underlying immunodeficiency, history of meningitis, encephalitis, septic shock, life-threatening soft tissue infection, more than one pneumonia.
- •Known (or signs consistent with) sickle cell anemia, sickle cell trait, thalassemia or thalassemia trait, glucose-6-phosphate dehydrogenase deficiency.
- •Use of immunoglobulins or blood products within 3 months prior to enrolment.
- •History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- •Any other serious chronic illness requiring hospital specialist supervision
- •History of travel to a malaria-endemic country within the previous 12 months.
- •History of serious psychiatric condition that may affect participation in the study
- •Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 24 g (men) or 12 g (women) per day.
- •Suspected or known illicit drug abuse in the 5 years preceding enrolment.
- •Volunteers unable to be closely followed for social, geographic or psychological reasons.
- •Any other significant disease, disorder, finding at medical history, biochemistry, haematology tests, urine analysis results, clinical examination or electrocardiogram (ECG) which, in the opinion of the Investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
- •Difficulties with venepuncture for blood sampling at screening visit due to veins that easily collapse or roll, are too thin, or are hard to find.
- •Positive for hepatitis B surface antigen (HBs-antigen).
- •Seropositive for hepatitis C virus (antibodies to HCV).
- •Abnormal vital signs
- •Intake of medication that potentially interferes with the study intervention or rescue drugs
- •Residence in a malaria endemic area for 5 or more years continuously.
- •Prior receipt of malaria vaccine candidates or malaria challenge products.
- •Use of concomitant medication with anti-plasmodial activity within 30 days of study enrolment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin erythromycin, fluoroquinolones, or azithromycin).
- •Receipt of an investigational product in the 90 days preceding, or planned receipt during the study period.
- •Contraindication to the use of the following antimalarial medications: AP, artemether-lumefantrine, artesunate.
- •Use of medication interacting with AP (e.g. metoclopramide, tetracycline, rifampicin, rifabutin, efavirenz, or nevirapine).
- •Use of medication interacting with artemether-lumefantrine (e.g. disopyramide, quinidine, procainamide, amiodarone, rifampicin, carbamazepine, phenytoin, phenobarbital, haloperidol, domperidone, pimozide or pipamperone).
结局指标
主要结局
Efficacy endpoint Proportion of protected volunteers. Protection is defined as the absence of amplifying parasitaemia in the peripheral blood for +21 days following CHMI with PfSPZ Challenge (NF54) in volunteers receiving AP (250/100 mg) for chemoprophylaxis. Amplifying parasitaemia is defined as at least one qPCR result above 20 blood-stage parasites per ML followed by a second qPCR result with an at least 4-fold increased blood stage parasitaemia 24-48 hours apartPrimary safety endpoint Numbe
Efficacy endpoint Proportion of protected volunteers. Protection is defined as the absence of amplifying parasitaemia in the peripheral blood for +21 days following CHMI with PfSPZ Challenge (NF54) in volunteers receiving AP (250/100 mg) for chemoprophylaxis. Amplifying parasitaemia is defined as at least one qPCR result above 20 blood-stage parasites per ML followed by a second qPCR result with an at least 4-fold increased blood stage parasitaemia 24-48 hours apartPrimary safety endpoint Numbe
次要结局
- Secondary safety endpoint Occurrence of any related AE from time of AP/placebo D0 until the end of the study.
研究者
Alexandra Roth
Scientific
Universitaetsklinikum Tuebingen AöR
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ ChallengeHealthy volunteerscontrolled human malaria infection with PfSPZMedDRA version: 18.1Level: PTClassification code 10025494Term: Malaria prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2014-005510-34-DEMedicines for Malaria Venture
招募中
不适用
Testing a Biometric Identification System to Improve Malaria Vaccine CompletionNCT07261280University of Michigan4,715
已完成
Unknown
Monthly versus three doses malaria chemoprophylaxis in pregnancy at Lautech Teaching Hospital Osogbo, a randomised controlled studyMalariaPACTR202304768950531AYODELE KABIR ALAO242
已完成
不适用
Effectiveness of a Malaria treatment and prevention training program on Patent Medicine Vendor's knowledge, attitudes and practicesMalariaPACTR201508001215416292
已完成
不适用
Drug resistance studies of antimalarial medicines.CTRI/2017/11/010703WHO GMP225